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rch 20, 2013.his study investigated the signiﬁcance of the serum high-sensitivity cardiac troponin T (hs-cTnT) marker for
prediction of adverse events in hypertrophic cardiomyopathy (HCM).Background Although serum cardiac troponins as sensitive and speciﬁc markers of myocardial injury have become
well-established diagnostic and prognostic markers in acute coronary syndrome, the usefulness of hs-cTnT for
prediction of cardiovascular events in patients with HCM is unclear.Methods We performed clinical evaluation, including measurements of hs-cTnT in 183 consecutive patients with HCM.Results Of 183 HCM patients, 99 (54%) showed abnormal hs-cTnT values (>0.014 ng/ml). During a mean follow-up of
4.1  2.0 years, 32 (32%) of the 99 patients in the abnormal hs-cTnT group, but only 6 (7%) of 84 patients
with normal hs-cTnT values, experienced cardiovascular events: cardiovascular deaths, unplanned heart failure
admissions, sustained ventricular tachycardia, embolic events, and progression to New York Heart Association
functional class III or IV status (hazard ratio [HR]: 5.05, p < 0.001). Abnormal hs-cTnT value remained an
independent predictor of these cardiovascular events after multivariate analysis (HR: 3.23, p ¼ 0.012). Furthermore,
in the abnormal hs-cTnT group, overall risk increased with an increase in hs-cTnT value (HR: 1.89/hs-cTnT 1 SD
increase in the logarithmic scale, 95% conﬁdence interval: 1.13 to 3.15; p ¼ 0.015 [SD: 0.59]).Conclusions In patients with HCM, an abnormal serum concentration of hs-cTnT is an independent predictor of adverse outcome,
and a higher degree of abnormality in hs-cTnT value is associated with a greater risk of cardiovascular
events. (J Am Coll Cardiol 2013;62:1252–9) ª 2013 by the American College of Cardiology FoundationHypertrophic cardiomyopathy (HCM) is a primary myo-
cardial disorder with a broad spectrum of clinical presenta-
tions (1–3). The natural history of HCM varies from an
asymptomatic and benign clinical course to sudden prema-
ture death. Several observations in community-based cohorts
have shown that not only sudden death, but also heart failure
and stroke related to HCM, were important adverse events
(4–9). Although several clinical markers are accepted for risk
stratiﬁcation in patients with HCM, including previous
cardiac arrest, family history of sudden death, syncope,
degree of left ventricular (LV) wall thickness, basal outﬂow
obstruction, and congestive symptoms, risk stratiﬁcation inand Geriatrics, Kochi Medical School, Kochi,
edicine, Kochi Medical School, Kochi, Japan;
Medical School, Kochi, Japan. All authors have
hips relevant to the contents of this paper to
; revised manuscript received March 19, 2013,HCM is still not sufﬁcient to identify patients at high risk
for these morbid events (6,10–14).
Cardiac troponins, including cardiac troponin T and
troponin I, as sensitive and speciﬁc markers of myocardial
injury, are well-established diagnostic and prognostic
markers in acute coronary syndrome. These troponins have
been reported to predict adverse outcome in patients with
heart failure even in the absence of coronary artery stenosis
(15–17). However, the usefulness of high-sensitivity cardiac
troponin T (hs-cTnT) for prediction of adverse clinical
events in patients with HCM is unclear.Methods
Patients. Patients were diagnosed as having HCM between
1982 and September 2010 at Kochi Medical School
Hospital. In this study, we performed clinical evaluation,
including measurements of hs-cTnT in 193 consecutive
patients with HCM between October 2004 and September
2010. We excluded patients with evidence of coronary artery
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1253disease (8 patients with a history of percutaneous coronary
intervention) and patients with renal failure (8 patients with
serum creatinine 3 mg/dl). The ﬁnal study population
consisted of 183 patients.
The diagnosis of HCM was based on echocardiographic
demonstration of unexplained LV hypertrophy (i.e., maximum
LV wall thickness 15 mm) in the absence of systemic
hypertension or other cardiac diseases (e.g., aortic stenosis or
storage disease) that could produce hypertrophy of such
magnitude (3). Informed consent was obtained from all patients
or their parents in accordance with the guidelines of the Ethics
Committee on Medical Research of Kochi Medical School.
Clinical evaluation. Evaluation of patients includedmedical
history, clinical examination, 12-lead electrocardiography,
and M-mode, 2-dimensional (2-D), and Doppler echocardi-
ography. Maximum LV wall thickness was deﬁned as the
greatest thickness in any single segment. Left ventricular
end-diastolic diameter (LVEDD) and left ventricular end-
systolic diameter (LVESD) were measured from M-mode
and 2-D images obtained from parasternal long-axis views,
and fractional shortening (%FS ¼ [LVEDD  LVESD]/
LVEDD 100) was calculated. LV outﬂow tract gradient
was calculated from continuous-wave Doppler using the
simpliﬁed Bernoulli equation.
For survival analysis, 3 modes of HCM-related death were
deﬁned: 1) sudden and unexpected death, in which collapse
occurred in the absence of or <1 h from the onset of symp-
toms in patients who previously experienced a relatively stable
or uneventful clinical course; 2) heart failure–related death,
which was in the context of progressive cardiac decompen-
sation 1 year before death, particularly if complicated
by pulmonary edema or evolution to the end-stage phase;
and 3) stroke-related death, which occurred as a result of
probable or proven embolic stroke. Other morbid events
included: 1) hospitalization for heart failure; 2) embolic stroke
admission; 3) spontaneous sustained ventricular tachycardia
(VT) associated with hemodynamic instability or appropriate
implantable cardioverter-deﬁbrillator (ICD) discharge; and
4) progression to New York Heart Association (NYHA)
functional class III or IV status that required additional
treatment. Data on survival and clinical status of patients
were obtained during serial clinic visits or by direct commu-
nication with patients and their cardiologists for patients
who were followed up at other institutions.
Measurements of hs-cTnT. Peripheral venous blood
samples were collected for measurements of biomarkers at
the clinical evaluation. Plasma was separated by centrifuga-
tion at 3,500g for 15 min. Aliquots were stored at
80. Serum hs-cTnT was measured by Elecsys Troponin T
High Sensitive immunoassay (Roche Diagnostics Ltd.,
Rotkreuz, Switzerland). This hs-cTnT in our study
conforms to guideline (universal deﬁnition of myocardial
infarction) precision requirements: an increased value for
cardiac troponin is deﬁned as a measurement exceeding the
99th percentile of a normal reference population, and
optimal precision (coefﬁcient of variation) at the 99thpercentile decision limit should
be deﬁned as 10% (18). The
normal range of this troponin
marker in an apparently healthy
adult population is 0.014 ng/ml
(99th percentile) (19,20). The
limit of the blank of the hs-
cTnT assay, that is, the smallest
concentration of a measurement
that can be reliably measured
by an analytical procedure, is
0.003 ng/ml (19).
Statistical analysis. All data are
expressed as mean  SD or
frequency (percentage). Compa-
risons of clinical characteristics
between normal and abnormal
hs-cTnT groups were assessed
using Student’s t test for nor-
mally distributed variables. Pe-
arson’s chi-square test was used
for comparisons between cate-
gorical variables, and Fisher’s
exact test was used when ex-
pected frequency was <5. For
statistical analysis as a continuous variable of hs-cTnT,
logarithmic transformation was applied to serum hs-cTnT
values to obtain normal distribution. Differences in means
of continuous variable were assessed using Student’s t test or
1-way analysis of variance. Pearson’s correlation coefﬁcient
was used to study the relationship between hs-cTnT and
echocardiographic data.
All cardiovascular events were the composite of HCM-
related death and the previously described morbid events.
Composite heart failure events included heart failure–related
death, hospitalization for heart failure, and progression to
NYHA functional class III or IV status. Arrhythmic events
were the composite of sudden death, spontaneous sustained
VT associated with hemodynamic instability, and appro-
priate ICD discharge. Cardiac events were deﬁned as the
composite of the previously mentioned heart failure events
and arrhythmic events.
To determine the cutoff value of hs-cTnT for all
cardiovascular events, a receiver-operating characteristic
curve was constructed. Event-free estimates curves were
calculated by the Kaplan-Meier method, and the log-rank
test was used for comparison. Clinical characteristics were
all ﬁrst tested with univariate Cox proportional hazards
analysis, and all variables with a value <0.05 were then taken
forward to be considered for inclusion in the multivariate
model. Predictors included in the multivariate analysis for all
cardiovascular events were hs-cTnT, age, rhythm, NYHA
functional class, left atrial diameter, and LVESD. Predictors
in the multivariate model for cardiac events were hs-cTnT,
age, rhythm, NYHA functional class, syncope, left atrial
diameter, and LVESD. The model was constructed with
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1254a forward selection procedure, with any variable that
improved the likelihood ratio test statistic by an amount
equivalent to p < 0.05 included. A Cox proportional hazards
model was performed to estimate the hazard ratio (HR) for
an abnormal hs-cTnT value and to estimate the effect on
outcomes of the degree of increased hs-cTnT values. The
predicted probability of having an event at 1, 2, and 3 years
was calculated for each patient. This was done by obtaining
the baseline survival from the Cox model for the cohort at
each time point and calculating the increased risk associated
with increased levels of hs-cTnT values. To test whether the
serum hs-cTnT value was an independent predictor of risk,
multivariate analysis was performed. Statistical analyses were
performed with SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina).Results
Baseline characteristics. Clinical characteristics of the
patients in the present study are shown in Table 1. Patients
were from 13 to 88 years old (mean age: 61  15 years), and
114 (62%) of the patients were males. Of the 183 patients,
most patients were completely asymptomatic or mildly
symptomatic at the time of troponin measurements; 108
(59%) were NYHA functional class I, 65 (36%) were
NYHA class II, and only 5 (10%) were NYHA class III. No
patients were treated with alcohol septal ablation or myec-
tomy. Maximum LV wall thickness was 20.1  4 mm, and 3
patients had wall thickness 30 mm. Twenty-ﬁve (14%) ofTable 1 Serum Hs-cTnT and Baseline Characteristics in 183 HCM Pa
Total
(n ¼ 183)
Normal h
(0.
Age, yrs 61.2  15.3 58
Male 114 (62%) 4
Serum hs-cTnT*, ng/ml 0.015  0.008 0.00
Atrial ﬁbrillation 44 (24%)
NYHA functional class
I or II 173 (95%) 8
III 10 (5%)
Risk factors for SCD
Wall thickness 30 mm 3 (2%)
Rest LVOTO 30 mm Hg 25 (14%) 1
Family history of SCD 31 (17%) 1
Syncope 23 (13%)
Sustained VT/VF 3 (2%)
Echocardiographic data
Maximum LV wall thickness, mm 20.1  4.0 18
IVS, mm 15.6  4.4 14
PW, mm 10.9  1.9 10
LV end-diastolic diameter, mm 45.5  6.2 45
LV end-systolic diameter, mm 26.8  7.0 26
Fractional shortening, % 42.0  9.1 43
Left atrial diameter, mm 44.3  7.3 42
Values are mean  SD or n (%). *Data are shown as median  quartile.
HCM ¼ hypertrophic cardiomyopathy; hs-cTnT¼ high-sensitivity cardiac troponin T; IVS ¼ interventricular
York Heart Association functional class; PW ¼ posterior wall thickness; SCD ¼ sudden cardiac death; Vthe patients showed LV outﬂow tract obstruction (pressure
gradient 30 mm Hg), and 28 (15%) of the patients had
apical HCM. Forty-four (24%) of the patients had docu-
mentation of paroxysmal or chronic atrial ﬁbrillation.
Serum hs-cTnT ranged from 0.003 to 0.140 ng/ml.
Associations of hs-cTnT with age, maximum LV wall
thickness, LV size, %FS, and left atrial diameter in patients
with HCM are shown in Table 2. Serum hs-cTnT did not
have strong correlations with age, maximum LV wall
thickness, and left atrial diameter, but did have signiﬁcant
correlations with these characteristics. Table 3 shows the
hs-cTnT values with respect to clinical characteristics.
Serum hs-cTnT values were higher in patients with atrial
ﬁbrillation than in those with sinus rhythm. Higher
hs-cTnT levels were also observed in patients with LV
systolic dysfunction than in those without LV systolic
dysfunction. Among the 173 HCM patients without LV
systolic dysfunction, serum hs-cTnT values were signiﬁ-
cantly lower in patients with apical HCM than in patients
with other subtypes of HCM. Serum hs-cTnT was signif-
icantly higher with respect to progressive severity of heart
failure symptoms, as judged by NYHA functional class.
We divided the patients into 2 groups by hs-cTnT values:
a normal hs-cTnT group (hs-cTnT 0.014 ng/ml) and an
abnormal hs-cTnT group (>0.014 ng/ml) (Table 1). The
percentage of patients with atrial ﬁbrillation in the abnormal
hs-cTnT group was higher than that in the normal hs-cTnT
group. More patients with abnormal hs-cTnT values expe-
rienced signiﬁcant dyspnea (NYHA functional class III).tients
s-cTnT (n ¼ 84)
014 ng/ml)
Abnormal hs-cTnT (n ¼ 99)
(>0.014 ng/ml) p Value
.1  14.4 63.9  15.5 0.010
7 (56%) 67 (68%) 0.103
7  0.004 0.025  0.018 <0.001
8 (10%) 36 (36%) <0.001
0.022
3 (99%) 90 (91%)
1 (1%) 9 (9%)
0 (0%) 3 (3%) 0.251
1 (13%) 14 (14%) 0.837
2 (14%) 19 (19%) 0.378
6 (7%) 17 (17%) 0.041
0 (0%) 3 (3%) 0.251
.9  2.9 21.1  4.6 <0.001
.1  3.6 16.8  4.6 <0.001
.4  1.5 11.4  2.1 <0.001
.5  5.4 45.5  6.9 0.999
.2  5.5 27.2  8.0 0.334
.0  7.6 41.0  10.2 0.126
.2  6.1 46.1  7.8 <0.001
wall thickness; LV ¼ left ventricular; LVOTO ¼ left ventricular outﬂow tract obstruction; NYHA ¼ New
T/VF ¼ ventricular tachycardia/ventricular ﬁbrillation.
Table 2
Correlations Between Hs-cTnT and
Echocardiographic Data in 183 HCM Patients
r Value p Value
Age 0.252 0.001
Maximum LV wall thickness 0.341 <0.001
LV end-diastolic diameter 0.061 0.409
LV end-systolic diameter 0.131 0.078
Fractional shortening 0.138 0.063
Left atrial diameter 0.414 <0.001
Abbreviations as in Table 1.
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1255Results of echocardiography showed that interventricular
septal wall, posterior wall, and maximum LV wall thick-
nesses were greater, and left atrial diameter was larger in
patients with abnormal hs-cTnT levels than in patients with
normal hs-cTnT levels. There were more syncope patients
in the abnormal hs-cTnT group, and all of the patients with
wall thickness 30 mm and all of the patients with a history
of sustained VT belonged to the abnormal hs-cTnT group.
Measurements of hs-cTnT and adverse cardiovascular
events. The mean follow-up of the patient cohort was
4.1  2.0 years. There were 9 cardiovascular deaths,
including sudden death in 4 patients, heart failure death in
3 patients, and embolic stroke death in 2 patients, all of
which occurred in the abnormal hs-cTnT group (Table 4,
Fig. 1A). A receiver-operating characteristic curve of hs-
cTnT level to predict all cardiovascular events showed that
the best cutoff value of this marker was 0.014 ng/ml, and the
area under the curve was 0.77 (Fig. 2); this cutoff level was
the same as the normal range in a healthy adult population.
Overall, 38 (21%) of the 183 patients had cardiovascularTable 3
Serum Hs-cTnT Values in 183 HCM Patie
to Clinical Characteristics
Sex, (n ¼ 183)
Male (n ¼ 114)
Female (n ¼ 69)
Atrial ﬁbrillation (n ¼ 183)
Present (n ¼ 44)
Absent (n ¼ 139)
LV systolic dysfunction (n ¼ 183)
Present (n ¼ 10)
Absent (n ¼ 173)
Subtypes in HCM without LV systolic dysfunction, (n ¼ 173)
HCM with obstruction,* (n ¼ 33)
HCM without obstruction (n ¼ 112)
Apical HCM (n ¼ 28)
NYHA functional class (n ¼ 183)
I (n ¼ 108)
II (n ¼ 65)
III (n ¼ 10)
Values are median  quartile. *HCM with obstruction includes LV outﬂow o
Abbreviations as in Table 1.events (the composite of HCM-related death and the
morbid events including embolic stroke): 32 (32%) of the 99
patients in the abnormal hs-cTnT group, but only 6 (7%) of
the 84 patients in the normal hs-cTnT group (HR: 5.05,
95% conﬁdence interval [CI]: 2.11 to 12.09, p < 0.001)
(Table 4, Fig. 1B). Abnormal concentration of hs-cTnT
predicted all cardiovascular events with a sensitivity of
84%, speciﬁcity of 54%, positive predictive value of 32%,
negative predictive value of 93%, and accuracy of 60%. In the
normal hs-cTnT group, no patient with levels <0.006 ng/ml
experienced any cardiovascular events. Similarly, 29 (16%) of
the 183 patients had cardiac events (cardiovascular events
excluding embolic stroke death or admission): 27 (27%) of
the 99 patients in the abnormal hs-cTnT group, but only 2
(2%) of the 84 patients in the normal hs-cTnT group (HR:
12.56, 95% CI: 2.99 to 52.82, p < 0.001) (Table 4, Fig. 1C)
(sensitivity of 93%, speciﬁcity of 53%, positive predictive
value of 27%, negative predictive value of 98%, and accuracy
of 60%). In the normal hs-cTnT group, no patient with
levels <0.011 ng/ml experienced cardiac events. In 2
patients with cardiac events, 1 patient with hs-cTnT 0.011
ng/ml underwent hospitalization for heart failure, and
another patient with hs-cTnT 0.014 ng/ml had hospitali-
zation for heart failure before ICD discharge. Furthermore,
patients with abnormal hs-cTnT values had signiﬁcantly
more frequent heart failure events. In contrast, frequency of
arrhythmic events in the abnormal hs-cTnT group was not
signiﬁcantly higher than that in the normal hs-cTnT group,
as shown in Table 4. Multivariate analysis showed that
abnormal hs-cTnT value was an independent predictor of
all cardiovascular events (HR: 3.23, 95% CI: 1.29 to 8.10,nts With Respect
Serum hs-cTnT (ng/ml) p Value
0.016  0.009
0.140
0.014  0.007
0.023  0.017
<0.001
0.013  0.006
0.030  0.021
0.012
0.015  0.007
0.018  0.010
0.016  0.009 0.001
0.008  0.005
0.015  0.007
0.016  0.010 <0.001
0.055  0.036
bstruction and midventricular obstruction.
Table 4 Cardiovascular Events in 183 Patients With Normal hs-cTnT Values and With Abnormal Hs-cTnT Values (Univariate Analysis)
Total (n ¼ 183)
Normal hs-cTnT (n ¼ 84)
(0.014 ng/ml)
Abnormal hs-cTnT (n ¼ 99)
(>0.014 ng/ml) Hazard Ratio 95% CI p Value
All cardiovascular events 6 32 5.05 2.11–12.09 <0.001
Cardiovascular deaths 0 9 NA d d
Cardiac events 2* 27y 12.56 2.99–52.82 <0.001
Heart failure events 2 24 11.16 2.64–47.21 0.001
Arrhythmic events 1 7 5.81 0.72–47.30 0.100
*One patient had both a heart failure event and an arrhythmic event. yFour patients had both heart failure events and arrhythmic events.
CI ¼ conﬁdence interval; other abbreviation as in Table 1.
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1256p ¼ 0.012). Other variables that were found to be inde-
pendently associated with all cardiovascular events were
NYHA functional class and left atrial diameter. For reclas-
siﬁcation analysis, integrated discrimination improvement
(IDI) was used to access the improvement between models
with and without hs-cTnT, and IDI was 0.033 (p ¼ 0.056).
Similarly, abnormal hs-cTnT value and NYHA functional
class also remained independent predictors of cardiac events
(HR: 10.84, 95% CI: 2.53 to 46.39, p ¼ 0.001).
In the abnormal hs-cTnT group, the overall risk of
cardiovascular events increased with an increase in the hs-
cTnT value (Fig. 3). After logarithmic transformation of
serum hs-cTnT values as a continuous variable, HR was
1.89/hs-cTnT 1 SD increase in the logarithmic scale (95%
CI: 1.13 to 3.15, p ¼ 0.015 [SD: 0.59]). When groups were
allocated according to the degree of abnormality in hs-cTnT
value (lower abnormal hs-cTnT: 0.015 to 0.018 ng/ml,
n ¼ 32; middle abnormal hs-cTnT: 0.019 to 0.030 ng/ml,
n ¼ 32; and upper abnormal hs-cTnT: 0.031 to 0.140 ng/
ml, n ¼ 35), clinical course was signiﬁcantly worse in
patients with higher hs-cTnT values (Figs. 4A and 4B).
Table 5 shows the signiﬁcant predictors of cardiovascular or
cardiac events after multivariate analysis: frequency of
morbid events seemed to increase with higher hs-cTnT
values.
As a continuous variable of hs-cTnT, this biomarker was
also signiﬁcantly associated with all cardiovascular events in
both univariate and multivariate Cox proportional hazards
regression analyses, and the odds ratios were 2.66 (95%
CI: 1.86 to 3.80) and 1.59 (95% CI: 1.08 to 2.33),
respectively. Similarly, the continuous variable of this
troponin marker was signiﬁcantly associated with cardiac
events, and the odds ratios in univariate and multivariate
analyses were 2.99 (95% CI: 1.99 to 4.49) and 1.97 (95%
CI: 1.29 to 3.03), respectively.
Discussion
There is little information on the utility of troponins as
prognostic markers in HCM. The main ﬁndings of this
study are that an abnormal hs-cTnT value itself and the
degree of abnormality in hs-cTnT value are associated with a
greater risk of adverse cardiovascular events. This biomarker
seems to be useful as an additive monitoring parameter in
patients with HCM.HCM is characterized by a heterogeneous clinical course
ranging from asymptomatic status with normal life expec-
tancy to severe heart failure, stroke caused by atrial ﬁbrilla-
tion, and sudden cardiac death (1–3). Although sudden
death is the most catastrophic event, a signiﬁcant proportion
of patients with HCM in a regional cohort largely free of
referral bias had heart failure and embolic complications
(4–9). In this study, during a follow-up of 4.1  2 years,
HCM-related deaths occurred in 9 patients (including
sudden death in 4 patients). The annual mortality rate in the
present study was 1.2% (0.5% for sudden death), which is in
accordance with previously reported data obtained from
community-based cohorts for HCM (4–8). Several risk
factors for sudden cardiac death, including degree of LV
hypertrophy, family history of sudden death, and unex-
plained syncope, have been established by tertiary institutes
(1–3,10,11). In addition, advanced age and the presence of
atrial ﬁbrillation, basal outﬂow obstruction, and congestive
symptoms were found to be clinically important predictors
of HCM mortality or stroke (5,8,12–14). However, risk
stratiﬁcation in HCM is still limited because the positive
predictive values of these clinical markers for adverse events
were not high, and this difﬁculty in prediction is thought to
be due to markedly diverse heterogeneity of clinical
phenotypes in HCM.
In the present study, we divided the patients into 2 groups
by hs-cTnT values. The cutoff value was deﬁned as
0.014 ng/ml because the normal range is 0.014 ng/ml
(99th percentile) in the system for measuring hs-cTnT, and
this cutoff value of 0.014 ng/ml was also determined by a
receiver-operating characteristic curve of hs-cTnT to predict
all cardiovascular events. Assessment of the relationships of
serum hs-cTnT levels with baseline clinical characteristics
showed that abnormal hs-cTnT value was associated
with ﬁndings supporting clinical deterioration in HCM,
including presence of atrial ﬁbrillation, severity of heart
failure symptoms as judged by NYHA functional class,
prevalence of syncope, greater wall thickness, and larger left
atrial diameter. Moreno et al. (21) recently reported in their
cross-sectional HCM study that clinical variables correlated
with hs-cTnT and showed that increased hs-cTnT serum
levels were associated with different conditions related to the
severity of disease; hs-cTnT was increased in patients with
severe dyspnea, and hs-cTnT was positively correlated with
maximum LV wall thickness.
Figure 2
A Receiver-Operating Characteristic Curve of hs-cTnT
to Predict All Cardiovascular Events
AUC ¼ 0.77. Cutoff value of hs-cTnT ¼ 0.014 ng/ml. AUC ¼ area under the curve;
other abbreviations as in Figure 1.
Figure 1
Freedom from CV deaths, All CV Events,
and Cardiac Events
(A) Kaplan-Meier unadjusted estimates of freedom from cardiovascular (CV)
deaths in 183 hypertrophic cardiomyopathy HCM patients according to normal
(0.014 ng/ml) and abnormal (>0.014 ng/ml) values of hs-cTnT. (B) Kaplan-
Meier unadjusted estimates of freedom from all CV events in 183 HCM patients
according to the normal (0.014 ng/ml) and abnormal (>0.014 ng/ml) values of
hs-cTnT. (C) Kaplan-Meier unadjusted estimates of freedom from cardiac events in
183 HCM patients according to normal (0.014 ng/ml) and abnormal (>0.014
ng/ml) values of hs-cTnT. Hs-cTnT ¼ high-sensitivity cardiac troponin T.
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1257For the prediction of cardiovascular outcome, patients with
abnormal hs-cTnT values had signiﬁcantly more frequent
adverse events, and abnormal hs-cTnT andNYHA functional
class were independent predictors of both cardiovascular and
cardiac events. Furthermore, the risk of adverse cardiovascular
events seemed to be greater with an increase in the degree of
abnormality in hs-cTnT values. These results were predomi-
nantly driven by the development of heart failure. Kawahara
et al. (17) reported that a high concentration of hs-cTnT was
an independent prognostic predictor in heart failure patients
with nonischemic dilated cardiomyopathy. Our study ﬁndings
showed that the serum hs-cTnT marker was also useful to
manage patients with HCM. In contrast, for arrhythmic
events, abnormal hs-cTnTdid not reach statistical signiﬁcance
probably because of the small number of these events in this
study. All of the patients with a history of sustained VT had
abnormal values of hs-cTnT, and 88% (7 of 8 patients) of the
arrhythmic events that occurred during follow-up were in the
abnormal hs-cTnT group.
Although the mechanisms of myocyte injury and release
of hs-cTnT in HCM remain unresolved, we speculate
that they may be caused by relative myocardial ischemia
resulting from an imbalance between inappropriate hyper-
trophy of the myocardium and insufﬁcient coronary arterial
supply. Petersen et al. (22) reported that patients with
HCM showed a reduced myocardial perfusion reserve, as
assessed by magnetic resonance imaging (MRI), that was in
proportion to the magnitude of hypertrophy. Furthermore,
they found that the decreased prevalence of myocardial
ﬁbrosis as assessed by delayed contrast-enhanced MRI was
accompanied by an increased hyperemic myocardial blood
Table 5
Multivariate Analysis of All Cardiovascular Events or
Cardiac Events
Hazard Ratio 95% CI p Value
All cardiovascular events
Lower abnormal hs-cTnT 2.94 0.98–8.84 0.055
Middle abnormal hs-cTnT 3.06 1.02–9.13 0.046
Upper abnormal hs-cTnT 3.67 1.31–10.25 0.013
NYHA class II 4.34 1.96–9.59 <0.001
NYHA class III 22.78 7.50–69.18 <0.001
Left atrial diameter 1.08 1.03–1.13 0.001
c Statistics 0.84 0.78–0.91
Cardiac events
Lower abnormal hs-cTnT 7.47 1.44–38.65 0.017
Middle abnormal hs-cTnT 13.74 2.92–64.59 <0.001
Upper abnormal hs-cTnT 12.14 2.56–57.49 0.001
NYHA class II 5.30 2.03–13.86 <0.001
NYHA class III 57.18 16.48–198.41 <0.001
c Statistics 0.86 0.79–0.93
Abbreviations as in Tables 1 and 4.
Figure 4
All CV and Cardiac Event-Free Rates Allocated
According to the Degree of Abnormality in
hs-cTnT Value
(A) CV event-free rate: normal hs-cTnT value: 0.014 ng/ml, lower abnormal
hs-cTnT value: 0.015 to 0.018 ng/ml; middle abnormal hs-cTnT value: 0.019
to 0.030 ng/ml; upper abnormal hs-cTnT value: 0.031 to 0.140 ng/ml.
(B) Cardiac event-free rate: normal hs-cTnT value: 0.014 ng/ml; lower
abnormal hs-cTnT value: 0.015 to 0.018 ng/ml; middle abnormal hs-cTnT value:
0.019 to 0.030 ng/ml; upper abnormal hs-cTnT value: 0.031 to 0.140 ng/ml.
Abbreviation as in Figure 1.
Figure 3
Probability of All CV Events on the Basis of Annual
Risk and Degree of Abnormality in hs-cTnT Value in
99 HCM Patients With Abnormal hs-cTnT Values
Predicted probability of all CV events at 1, 2, and 3 years on the basis of the
degree of abnormality in hs-cTnT value, plotted against the X-axis on the right. The
bar charts represent the number of the patients with this concentration of hs-cTnT,
plotted on the X-axis on the left. Abbreviations as in Figure 1.
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1258ﬂow. This observation suggests a pathophysiological link
between repetitive hypoperfusion during stress and devel-
opment of myocardial ﬁbrosis. Recently, the presence of
late gadolinium enhancement in MRI has been reported to
be associated with arrhythmic events and heart failure
symptoms in HCM patients, and the presence of this
ﬁbrosis indicated by MRI seems to be a novel marker for
identifying those at risk of progressive disease (23–28).
Although we did not evaluate the presence and extent of
ﬁbrosis using late gadolinium-enhanced MRI, Moreno
et al. reported that hs-cTnT levels were raised in HCM
patients with gadolinium enhancement in cardiac MRI (21).
From these ﬁndings, the serum hs-cTnT marker may reﬂect
microvessel ischemia and subsequent ﬁbrosis in HCM.
Study limitations. First, this was a single-center study, and
it was not prospective. Second, our study cohort differed
from tertiary center cohorts in which referral patterns were
skewed toward patients perceived to be at high risk. The
present study was a community-based cohort and included
less high-risk patients than those in major referral centers.
That is, prevalence of HCM with obstruction was low, and
only a few patients experienced arrhythmic events during
follow-up in our study. Therefore, it remains unclear
whether the hs-cTnT marker in HCM patients at high risk,
particularly for sudden death, was useful. Third, the size of
our population was small, and the study was not designed
with a priori calculations with respect to sample size or
statistical power. As such, the ﬁndings need to be conﬁrmed
in larger and prospectively designed studies. Fourth, this
biomarker was originally introduced clinically for earlier
diagnosis of acute myocardial infarction, and we did not
perform angiograms in all patients. However, the 183
enrolled patients in this study did not show any evidence of
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1259ischemic heart disease, and coronary artery obstruction was
denied by angiograms in 55 patients or thallium-201
myocardial scintigrams in 17 patients. All 38 patients who
had extremely high hs-cTnT values (>0.10 ng/ml) and who
presented with LV systolic dysfunction or had cardiac events
(the composite of the heart failure events and arrhythmic
events) were examined by either angiography or thallium-
201 myocardial scintigraphy, and no one had coronary
artery obstruction. Therefore, we believe that coronary artery
disease was not related to their clinical deteriorations in the
present study. Fifth, the reasonable cutoff value might
depend on various situations, such as different cohorts
(tertiary center cohorts vs. community-based cohorts) or
different outcomes (arrhythmic events vs. heart failure
events). Furthermore, it might be better to use sex-speciﬁc
cutoff values, but we were unable to use different cutoff
levels for distinction between sexes because of the small study
cohort. Finally, we did not have serial measurements of hs-
cTnT in this study, and we had no data on whether there
were any interventions to reduce the concentrations of this
biomarker, which might have led to improved outcome in
patients with HCM.
Conclusions
In patients with HCM, an abnormal serum concentration of
hs-cTnT is an independent predictor of adverse outcome,
and a higher degree of abnormality in hs-cTnT values is
associated with a greater risk of cardiovascular events.
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